Psychiatric Times

Clinicians can ensure high-quality care by remaining informed about legal and ethical considerations in navigating patient privacy dilemmas. Learn more about HIPAA Privacy Rule issues in our October cover story! https://lnkd.in/eHPkvygq

Dr. Jelena Kunovac shares a unique perspective after working in collaboration with Karuna Therapeutics & Bristol Myers Squibb on the EMERGENT trials that led to the FDA approval of Cobenfy. Dr. Kunovac had advice for clinicians interested in preparing themselves to prescribe Cobenfy to patients: "First, they have to familiarize themselves with the adverse events and understand what is the medication about—that it is consists of 2 different compounds," she said. "And in order to be able to explain to the patient what they're going to be taking, you have to know it yourself." Check out the Q&A below at Psychiatric Times!

Do you want to be featured in our online series and potentially in print for an upcoming Special Report? Check out our October theme: Psychiatric Best Practices! https://lnkd.in/gYEimWdS

The October issue of Psychiatric Times is now live! This month, we address ethical issues concerning the HIPAA Privacy Rule and the Goldwater Rule. Download the issue now and follow along as articles are shared throughout the month. https://lnkd.in/g8JjN_nU

Teen pregnancy is often viewed through a very negative lens. This book seeks to reduce that stigma. https://lnkd.in/e7X8-mbN

"Galaxy Gas": Learn more about the latest viral substance abuse trend. https://lnkd.in/ehb4vheH

Mental health clinicians can help empower patients via tools like diet, including the MIND Diet. Mena Mirhom, MD, FAPA shares more on lifestyle and mental health. https://lnkd.in/gD943wZb

Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic. https://lnkd.in/e3ivBJXv

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia. Psychiatric Times sat down with Peter Vanderklish, PhD, CSO at Spinogenix, Inc. to learn more about this new potential treatment option. https://lnkd.in/gYP3qgHq

On September 26, 2024, the US Food and Drug Administration?approved Cobenfy?(xanomeline and trospium chloride), formerly known as KarXT, for the treatment of schizophrenia in adults. In doing so, it represents the first drug with a novel mechanism in decades, as it selectively targets the M1 and M4 receptors without blocking D2 receptor. Although?Psychiatric Times?and other medical publications have?reviewed the research?leading to the approval, how prepared are clinicians to discuss the agent with patients and consider its use in regular practice?